Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607283 | 0.89 | PTGS2 (0.57) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL7502827 | 0.85 | NR4A2 (0.62) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL7508637 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL6308685 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL6860700 | 0.83 | PTGS1 (0.41) | PTGS2PTGS1CA9NR4A2 | |
| SCHEMBL7503465 | 0.83 | PTGS2 (0.62) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL9097538 | 0.82 | NR4A2 (0.56) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL7506197 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL6308379 | 0.81 | PTGS2 (0.58) | PTGS2PTGS1MAOAMAOBCA1 | |
| SCHEMBL7505178 | 0.81 | RXRA (0.62) | PTGS2PTGS1NR4A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885PTGS1 9/4885MAOA 307/4885 |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885PTGS1 9/4885MAOA 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.